Conditions: Lymphoma, B-Cell
Keywords: B-cell Non-Hodgkin's Lymphoma NHL
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 10
Healthy volunteers: no

Brief summary:
To assess the tolerability and the initial safety profile of Inotuzumab Ozogamicin (CMC-544) in combination with Rituximab in patients with B-Cell Non-Hodgkin's lymphoma (NHL).

Detailed description:

Arms:
arm 1: None

Interventions: intervention 1: Inotuzumab Ozogamicin (CMC-544) intervention 2: Rituximab (Rituxan)
Intervention descriptions: intervention 1: 1.8 mg/m2, IV on day 2 of each 28 day cycle; up to 8 cycles unless PD, unacceptable toxicity, or subject's refusal occurs. intervention 2: 375 mg/m2, IV on day 1 of each 28 day cycle; up to 8 cycles unless PD, unacceptable toxicity, or subject's refusal occurs.

Protocol document: